Abstract
Introduction

Increasing attention has been paid to the metabolic effects of telmisartan, an angiotensin II receptor blocker (1-3). However, as far as we know, there have been no reports indicating that telmisartan exhibited an unequivocal improvement in glycemic control associated with a marked reduction in insulin requirement. Here, we describe such a patient that showed marked glycemic improvement on response to telmisartan administration. The patient adhered to perform self monitoring of blood glucose (SMBG) 3-4 times a day.
This enabled us to make meticulous observations of the process of glycemic improvement. He was also under treatment with risperidone, an atypical antipsychosis drug, which has been reported to induce metabolic abnormalities (4, 5) . We discuss the possibility that telmisartan may have reversed the metabolic abnormalities induced by risperidone.
Case Report
We report a 51-year-old man whose antihypertensive agent was switched from candesartan to telmisartan. He 
F i g u r e 1 . Cl i n i c a l c o u r s e s h o wi n g t h e c h a n g e s i n Hb A1 c , a v e r a g e o f p r e p r a n d i a l b l o o d g l u c o s e , b o d y we i g h t a n d i n s u l i n d o s e . P r e p r a n d i a l b l o o d g l u c o s e l e v e l s we r e c a l c u l a t e d a s t h e a v e r a g e o f 4 2 d e t e r mi n a t i o n s e v e r y 2 we e k s .
was still not good (HbA1c levels in the preceding 3 months were in the range of 7.8-8.6% Fig. 1 . The body weight after reswitch to candesartan did not exceed that before the reswitch.
T a b l e 1 . I n s u l i n S e c r e t o r y F u n c t i o n
As shown in Fig. 1 We first review studies in the clinical situation. There has been increasing evidence that suggests improvement in glycemic control (1, 2, 8, 9) and favorable effects on lipid profile including reduction of LDL-cholesterol (9, 10) by telmisartan administration. Quite recently, Makita et al (11) showed that telmisartan rather than candesartan may have a larger impact on obesity-related disease, demonstrating that telmisartan decreases fasting blood glucose and body weight. The decrease in LDL-cholesterol following telmisartan administration may be also explained by its ameliorating effect on over-weight related parameters (9) .
As analogous data in an animal experiment, Araki (11, 13, 14) . Different from thiazolidinediones, telmisartan does not induce obesity (13) . Sugimoto et al (14) (17, 18) . Such various factors as PPARγ (19, 20) , some kinds of adipokines and uncoupling protein 1 (3, 11, 20, 21) are said to involve improving insulin sensitivity on telmisartan adminisatration. However, they do not seem to explain the extreme effects seen in our case.
On the other hand, increasing attention has been paid to the metabolic effects of risperidone (4, 5, (22) (23) (24) . Risperidone has been reported to decrease insulin sensitivity (22) , promote a weight gain (23) , raise LDL-cholesterol levels (23) and increase the risk of diabetes mellitus (24) . In other words, telmisartan and risperidone may have opposite effects on weight control, lipid metabolism and insulin sensitivity (22) (23) (24) . Although the mechanisms of metabolic impairment induced by risperidone have not been fully elucidated, the direct effect on β-cells of pancreas has been virtually denied (22) . As for possible mechanisms, the following have been suggested: insulin resistance due to body weight gain (23, 24) and a direct effect on insulin-sensitive target tissues (5) .
In this context, the phenomenon after the administration of telmisartan in the present case seems to be the reverse of the metabolic effects of risperidone. This interpretation could account for the extreme effects of telmisartan in our case. We therefore speculate that the metabolic effects of telmisartan seen in our case were brought about, at least partially, through overcoming the metabolic effects of risperidone.
In conclusion, we presented the marked insulin sparing effect of telmisartan in a patient with type 2 diabetes mellitus. As this patient was under treatment of risperidone, the metabolic effects of telmisartan seem to require further study with regard to its interaction with risperidone. To our knowledge, this is the first report suggesting the possibility that the metabolic effects of risperidone may be reversed with telmisartan administration.
